Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,